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The authors compared the suitability for endovascular repair
(EVAR) in patients with incidentally diagnosed and screen-
detected aneurysms. In view of the potential effects on the future
health economics of aneurysm screening and EVAR, this is a topic
of considerable interest. The study was initiated after the authors’
observation that screen-detected aneurysms tended to have longer
infrarenal necks. However, early abdominal aortic aneurysm
(AAA) detection did not lead to an increase in suitability for EVAR
in this study.
Before the outcome of this study is accepted, several issues
must be addressed. First, the study lacks a proper power analysis,
and with recruitment arms of 41 and 31 patients, a type II error is
imminent. One may further question the efficacy of the ultrasound
screening program to which the study population was exposed,
because the median aneurysm diameter upon referral was 65 mm
(range, 51-79 mm), after a mean of nine surveillance scans per
patient, typically spanning a minimum of 2 years. As a result, the
screen-detected aneurysms were relatively large at the time of
referral, whereas EVAR suitability is expected to be higher in
smaller AAAs. The study was conducted in a vascular center where
EVAR is not offered as a treatment option, and all patients under-eijn, MD, PhD, Nijmegen, The Netherlands
experience will tend to use rather rigid criteria for this treatment
option as compared with EVAR centers. Common indications for
surgery were applied in this study: aneurysm diameter larger than
55 mm, rapid expansion of more than 10 mm/y, or a tender
aneurysm. This is in accordance with most EVAR studies. The
determination of suitability for EVAR, however, depended on
the—rather poorly defined—manufacturer’s criteria for a single
device, whereas in most endovascular programs, EVAR eligibility is
determined on the basis of the availability of multiple devices. In
addition, suitability for EVAR is never an objective qualification,
irrespective of manufacturer’s guidelines, which are commonly
rather conservative (for understandable reasons). Many clinicians,
for instance, consider neck thrombus not to be a contraindication
to EVAR, although this was the second most common exclusion
criterion in this study. This may be an explanation for the low rates
of suitability for EVAR of 41% and 45% in the screen-detected and
incidentally diagnosed AAAs, respectively, whereas in many centers
60% of AAA patients receive an endograft. It is quite possible that
with more liberal criteria for EVAR, screen-detected aneurysms
would have shown a higher suitability rate than the incidentally
diagnosed aneurysms. Caution is therefore appropriate in the
interpretation and generalization of the outcome of this study.
